US Patent

US9931334 — Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Method of Use · Assigned to Vertex Pharmaceuticals Inc · Expires 2026-12-28 · 1y remaining

Vulnerability score 93/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects solid state forms of a specific chemical compound and methods for using it in pharmaceutical compositions.

USPTO Abstract

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Drugs covered by this patent

Kalydeco (IVACAFTOR) · Vertex Pharms Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4080`	—
`U-2376`	—	Kalydeco
`U-2276`	—	Kalydeco
`U-2276`	—	Kalydeco
`U-4068`	—
`U-4078`	—
`U-2575`	—	Kalydeco
`U-3429`	—	Kalydeco
`U-2575`	—	Kalydeco
`U-2376`	—	Kalydeco
`U-4068`	—
`U-4078`	—
`U-4080`	—

Patent Metadata

Patent number: US9931334
Jurisdiction: US
Classification: Method of Use
Expires: 2026-12-28
Drug substance claim: No
Drug product claim: Yes
Assignee: Vertex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.